PHAM QUANG X (CEO and Chairman) sold 1.8% of their position (3.60K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $50.7K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 10/14/2025ACC: 0001213900-25-098719
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-3.60K
Net shares
Net seller
$50.7K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
3.60K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−1.80K
Price / share
$14.02
Trade value
$25.24K
% of position
0.9%
10/9/2025
202.13K→200.33K
Common Stock
Direct
Shares
−1.80K
Price / share
$14.15
Trade value
$25.47K
% of position
0.9%
10/13/2025
200.33K→198.53K
Total
Net shares
−3.60K
Net value
-$50.71K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 10/9/2025 | S · Sale | −1.80K | $14.02 | $25.24K | 0.9% | 202.13K | 200.33K |
| Common Stock Direct | 10/13/2025 | S · Sale | −1.80K | $14.15 | $25.47K | 0.9% | 200.33K | 198.53K |
| Total | −3.60K | -$50.71K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported